VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization
Abstract Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates were 7% and 9% (p = 0.771) and the total number of collected stem cells were 7.0 × $ 10^{6} $ and 6.7 × $ 10^{6} $ per kg body weight (p = 0.710) for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized with G-CSF only..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Acta haematologica Polonica - 51(2020), 1 vom: 13. März, Seite 42-46 |
| Beteiligte Personen: |
Skerget, Matevz [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© 2020 Matevz Skerget et al., published by Sciendo |
|---|
| doi: |
10.2478/ahp-2020-0009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY006891519 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY006891519 | ||
| 003 | DE-627 | ||
| 005 | 20230811111331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230811s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.2478/ahp-2020-0009 |2 doi | |
| 035 | |a (DE-627)GRUY006891519 | ||
| 035 | |a (DE-B1597)ahp-2020-0009-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Skerget, Matevz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2020 Matevz Skerget et al., published by Sciendo | ||
| 520 | |a Abstract Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates were 7% and 9% (p = 0.771) and the total number of collected stem cells were 7.0 × $ 10^{6} $ and 6.7 × $ 10^{6} $ per kg body weight (p = 0.710) for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized with G-CSF only. | ||
| 700 | 1 | |a Skopec, Barbara |4 aut | |
| 700 | 1 | |a Sever, Matjaz |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta haematologica Polonica |d Sciendo, 2000 |g 51(2020), 1 vom: 13. März, Seite 42-46 |h Online-Ressource |w (DE-627)GRUY000550027 |w (DE-600)2704533-X |w (DE-576)379469510 |x 2300-7117 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2020 |g number:1 |g day:13 |g month:03 |g pages:42-46 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2478/ahp-2020-0009 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2020 |e 1 |b 13 |c 03 |h 42-46 | ||